Bibliometric analysis of research on secondary organic aerosols: A Science Citation Index Expanded-based analysis (IUPAC Technical Report)

This study was conceived to evaluate the global scientific output of secondary organic aerosol (SOA) research over the past 20 years and to assess the characteristics of the research patterns, tendencies, and methods in the papers. Data were based on the online version of Science Citation Index Expanded from 1992 to 2011. Publications referring to SOAs were assessed by distribution of the number of publications and times cited, source categories, source journals, author keywords, Key Words Plus, and the most cited publications in these years. By synthetic analysis of author keywords, Key Words Plus, titles, and abstracts, it was concluded that modeling is currently and will at least over the next decade continue to be the predominant research method to validate state-of-the-art knowledge of SOAs, and that the foci of SOA research will be the key precursors terpenes and isoprene, the mechanisms of oxidation and gas-phase reactions, and emission inventories

On the stratospheric chemistry of hydrogen cyanide

HCN profiles measured by solar occultation spectrometry during 10 balloon flights of the JPL MkIV instrument are presented. The HCN profiles reveal a compact correlation with stratospheric tracers. Calculations with a 2D-model using established rate coefficients for the reactions of HCN with OH and O(^1D) severely underestimate the measured HCN in the middle and upper stratosphere. The use of newly available rate coefficients for these reactions gives reasonable agreement of measured and modeled HCN. An HCN yield of ∼30% from the reaction of CH_3CN with OH is consistent with the measurements

Experimental and Computational Studies of the Kinetics of the Reaction of Atomic Hydrogen with Methanethiol

Article on experimental and computational studies of the kinetics of the reaction of atomic hydrogen with methanethiol

Effects of Once-Weekly Exenatide on Cardiovascular Outcomes in Type 2 Diabetes.

Abstract BACKGROUND: The cardiovascular effects of adding once-weekly treatment with exenatide to usual care in patients with type 2 diabetes are unknown. METHODS: We randomly assigned patients with type 2 diabetes, with or without previous cardiovascular disease, to receive subcutaneous injections of extended-release exenatide at a dose of 2 mg or matching placebo once weekly. The primary composite outcome was the first occurrence of death from cardiovascular causes, nonfatal myocardial infarction, or nonfatal stroke. The coprimary hypotheses were that exenatide, administered once weekly, would be noninferior to placebo with respect to safety and superior to placebo with respect to efficacy. RESULTS: In all, 14,752 patients (of whom 10,782 [73.1%] had previous cardiovascular disease) were followed for a median of 3.2 years (interquartile range, 2.2 to 4.4). A primary composite outcome event occurred in 839 of 7356 patients (11.4%; 3.7 events per 100 person-years) in the exenatide group and in 905 of 7396 patients (12.2%; 4.0 events per 100 person-years) in the placebo group (hazard ratio, 0.91; 95% confidence interval [CI], 0.83 to 1.00), with the intention-to-treat analysis indicating that exenatide, administered once weekly, was noninferior to placebo with respect to safety (P<0.001 for noninferiority) but was not superior to placebo with respect to efficacy (P=0.06 for superiority). The rates of death from cardiovascular causes, fatal or nonfatal myocardial infarction, fatal or nonfatal stroke, hospitalization for heart failure, and hospitalization for acute coronary syndrome, and the incidence of acute pancreatitis, pancreatic cancer, medullary thyroid carcinoma, and serious adverse events did not differ significantly between the two groups. CONCLUSIONS: Among patients with type 2 diabetes with or without previous cardiovascular disease, the incidence of major adverse cardiovascular events did not differ significantly between patients who received exenatide and those who received placebo. (Funded by Amylin Pharmaceuticals; EXSCEL ClinicalTrials.gov number, NCT01144338 .)

A kinetics investigation of several key tropospheric chemical reactions

Issued as Interim progress report, Progress report, and Final report, Project no. A-285

Laboratory studies of stratospheric reactions

Issued as Quarterly progress reports, nos. 1-2, Interim final report and Final report, Project no. A-357

Laboratory studies of tropospheric sulfur chemistry

Issued as final repor

Experimental and theoretical studies of potential new atmospheric sources and sinks of nitrous oxide

Issued as final repor

Comparative study of atmospheric sulfur budget in different natural environments

Issued as Annual reports [nos. 1-2], and Final report, Project G-35-62

1997 Atmospheric Chemistry Colloquium for Emerging Senior Scientists

DOE's Atmospheric Chemistry Program is providing partial funding for the Atmospheric Chemistry Colloquium for Emerging Senior Scientists (ACCESS) and FY 1997 Gordon Research Conference in Atmospheric Chemistr